Azamat M. Satybaldyev

Azamat M. Satybaldyev

Auto-generated profile, based on publicly available information

Azamat M. Satybaldyev

V.A. Nasonova Research Institute of Rheumatology

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2020 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
AAAnastasia Avdeeva
Anastasia Avdeeva
AMA. S. Misiyuk
A. S. Misiyuk
ASA. M. Satybaldyev
A. M. Satybaldyev
GLGalina Lukina
Galina Lukina
VSV. N. Sorotskaya
V. N. Sorotskaya
ENE. L. Nasonov
E. L. Nasonov
Objective: to analyze the results of tofacitinib (TOFA) therapy in real clinical practice according to the All-Russian Arthritis Registry (OREL). Subjects and methods. The OREL Registry included 347 patients (286 (82%) women and 61 (18%) men) with rheumatoid arthritis (RA) who initiated TOFA therapy. The male:female ratio was 1:4.7. The patients’ median age at onset of the disease was 42 years; its duration was 8 years. Most of the patients included in the registry had extended- (n=171 (52%)) or late- (n=148 (45%)) stage of RA. Results and discussion. Prior to initiation of TOFA therapy, RA activity according to DAS28 was high and moderate in 91 (64.5%) and 40 (28.4%) patients, respectively; the median DAS28 value was 5.5 [4.6; 6.2]; SDAI – 30.5 [21.4; 42.9], and CDAI – 28.2 [20.0; 37.1]. The use of TOFA was accompanied by significant decrease of disease activity. After 12 weeks, high RA activity was persistent in 32 (22.7%) patients; the number of patients with moderate activity increased to 77 (54.6%), that of those with low activity rose to 15 (10.6%); remission was observed in 17 (12.1%) patients. 216 (62.6%) and 76 (22%) patients received TOFA as first- and second-line therapy, respectively. TOFA was most frequently prescribed when tumor necrosis factor-á inhibitors (19.6%), rituximab (7.8%), tocilizumab (4.3%), and abatacept (5.2%) were insufficiently effective or poorly tolerated. Conclusion. The results of using TOFA in real clinical practice may suggest that the drug has high efficacy in patients with RA. TOFA can be used at a dose of 5 or 10 mg twice daily as both alone and in combination with disease-modifying anti-rheumatic drugs. TOFA showed similar efficacy in patients who had earlier taken biological agents and in those who had not.

27 April 2020 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
ASA. M. Satybaldyev
A. M. Satybaldyev
NDN. V. Demidova
N. V. Demidova
GGG. I. Gridneva
G. I. Gridneva
NNN. Yu. Nikishina
N. Yu. Nikishina
EGElena Gerasimova
Elena Gerasimova
ENE. L. Nasonov
E. L. Nasonov
Клиническая характеристика трех когорт раннего ревматоидного артрита с поздним началом (в возрасте 50 лет и старше). Обобщение 40-летнего опыта

2 September 2024 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
ENEvgeny L. Nasonov
Evgeny L. Nasonov
ASAzamat M. Satybaldyev
Azamat M. Satybaldyev
EOElvira N. Otteva
Elvira N. Otteva
TBTatiana Beketova
Tatiana Beketova
ABAndrey A. Baranov
Andrey A. Baranov
Giant cell arteritis (GCA) and polymyalgia rheumatica (RPM) are immune-mediated rheumatic disease (IMRDs), which typically develop in people over 50 years of age. Currently, GCA and PMR are considered within a single complex autoimmune-autoinflammatory pathology, defined as “GCA-PMR spectrum disease”. This was reflected in the development of general recommendations for pharmacotherapy within the framework of the “treat-to-tar get” strategy, although specific approaches to the treatment of patients with GCA and RPM differ depending on the clinical and pathogenetic characteristics of each nosological form. Glucocorticoids (GCs) are central to the treatment of GCA and RPM. Attention is drawn to the paradoxical discrepancy between the high effectiveness of GCs in the short term and the increasing severity of pathology associated with persistent inflammatory activity and the accumulation of organ damage induced by GCs in the long term, which indicates the need to improve therapy, primarily in the direction of optimizing the use of GCs. New opportunities for pharmacotherapy of GCA and RPM (as well as other IMRDs) are associated with the use of biologic agents that block the activity of cytokines involved in the immunopathogenesis of diseases, and in recent years, JAK (Janus kinase) inhibitors. Among pharmacological “targets,” special attention is drawn to interleukin (IL) 6, a pleiotropic cytokine involved in the development of inflammation, immune response, immunometabolism, cancerogenesis, vascular wall remodeling, etc. Currently, several biologic agents have been developed that are specific to both IL-6 receptor and IL-6: humanized monoclonal antibodies (mAbs) to the IL-6 receptor (tocilizumab), and human mAbs to IL-6 receptor (sarilumab and levilimab (BIOCAD)), humanized mAbs to IL-6 olokizumab (R-PHARM), etc. The article summarizes data regarding the effectiveness and safety of tocilizumab in GCA and RPM, recommendations for the use of IL-6 inhibitors in these diseases and discusses the prospects for further research.

1 January 2021 in Russian Annals of Ophthalmology
Verified
Journal Article
Closed access
AZA.N. Zhuravleva
A.N. Zhuravleva
ASA.M. Satybaldyev
A.M. Satybaldyev
RZRena A Zinchenko
Rena A Zinchenko
MKM.O. Kirillova
M.O. Kirillova
VKVitaly V. Kadyshev
Vitaly V. Kadyshev
Mutations and polymorphisms of the genes whose products are involved in the formation of extracellular matrix components can lead to the development of specific changes in the connective tissue of the eye in primary open-angle glaucoma (POAG). Understanding the nature of connective tissue pathology and its manifestations at the system level contributes to the development of specific markers of early detection and a personalized approach to the prevention and treatment of POAG. To study the associations between systemic manifestations of undifferentiated connective tissue dysplasia (uCTD) and the development of POAG based on clinical and molecular genetic studies. The observational study was conducted in the period from 2008 to 2021 (12 full years) and included retrospective data analysis of up to 15 years. The study involved 60 people with «suspected glaucoma» diagnosis and burdened heredity, who were divided into groups according to the severity of phenotypic signs of uCTD (on the T.I. Kadurina scale), as well as 15 people with «glaucoma» diagnosis whose morphological and immunohistochemical studies of the sclera were analyzed retrospectively. The comparison group consisted of 64 relatively healthy individuals. All patients underwent clinical-anamnestic, molecular-genetic, standard and special ophthalmological studies. Significant associations were revealed between the development of POAG, and the presence of clinical and phenotypic manifestations of uCTD, carriage of the GT genotype and the T allele of the rs8136803 (TIMP3) polymorphism, the AG genotype and the A allele of the rs652438 polymorphism (MMP12), the GA genotype and the A allele of the rs3825942 polymorphism (LOXL1). The specific features of preclinical morphofunctional changes and glaucoma progression can be determined by a hereditary predisposition to the pathology of the connective tissue of the eye. Testing of clinical-phenotypic and molecular-genetic signs of uCTD in patients with suspected glaucoma is promising in preclinical diagnosis, prognosis, and personalized approach to prevention and treatment.

24 June 2021 in Modern Rheumatology Journal
Verified
Journal Article
Open access
PDF file
ECE. V. Chetina
E. V. Chetina
ASA. M. Satybaldyev
A. M. Satybaldyev
GMG. A. Markova
G. A. Markova
ESE. Yu. Samarkina
E. Yu. Samarkina
MCM. V. Cherkasova
M. V. Cherkasova
Background. Rheumatoid arthritis (RA) is an autoimmune disease of unknown etiology, characterized by erosive arthritis (synovitis) and systemic inflammation. Janus kinase (JAK) inhibitors (JAKi) are small molecules that block major signal pathways of many cytokines a growth factors, associated with RA. Identification of patients sensitive to JAKi before treatment could significantly improve therapy outcomes. Currently it is not possible to predict JAKi efficacy in every patient, while some patients are non-responsive to the drug, other develop adverse effects. JAKi effect in RA patients has been recently associated with alterations in mitochondrial function and ATP production. Therefore, we hypothesized that baseline metabolic status of RA patients prior to drug administration can predict the therapeutic outcome.Objective: to investigate the predictive value of baseline expression of genes involved in energy generation in the blood of RA patients, for treatment response to JAKi.Patients and methods. We examined peripheral blood of 28 RA patients aged 52.2±15.6 years, average disease duration 3.5 years (range 0.6–19), treated with Tofacitinib (TOFA, 5–10 mg twice a day) during three months and 26 healthy age-matched control subjects. Clinical response was assessed by disease activity score (DAS28-ESR), immunological status by measurements of serum levels of anti-citrullinated protein antibodies (ACPA), rheumatoid factor (RF), and C-reactive protein (CRP). Gene expression was assessed in peripheral blood cells by realtime reverse-transcription polymerase chain reaction (RT-PCR). At baseline all patients had Steinbrocker radiographic stage II–III. Most patients (85.7%) were ACPA and RF positive. Thirteen patients had medium, others – high RA activity.Results and discussion. JAKi treatment significantly decreased the inflammatory disease activity according to DAS28. At the end of the study 17 patients demonstrated moderate disease activity (3.2<DAS28<5.1), 4 patients retained high disease activity while 7, attained remission (DAS28 <2.6). Disease remission, achieved on TOFA treatment, was accompanied by significant decrease in CRP and the number of swollen and tender joints. ESR values were not changed significantly. Gene expression analysis revealed that RA patients, which attained clinical remission after TOFA treatment, demonstrated significantly lower baseline expression of genes associated with glycolysis (pyruvate kinase, PKM2) and oxidative phosphorylation (succinate dehydrogenase, SDHB) compared to other examined RA patients, but higher expression of the abovementioned genes compared to control subjects. Moreover, RA patients who attained clinical remission demonstrated a trend to increase of these gene expressions within follow-up period, while in the rest of patients these gene expression was tending to downregulate.Conclusion. Clinical remission in RA patients treated with JAKi is associated with significantly lower baseline expression of genes associated with energy generation pathways (PKM2 and SDHB) compared to other examined subjects.

26 December 2024 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
ENE. L. Nasonov
E. L. Nasonov
TBTatiana Beketova
Tatiana Beketova
ASA. M. Satybaldyev
A. M. Satybaldyev
Giant cell arteritis (GCA) characterized by the paradoxical discrepancy between the high effectiveness of glucocorticoid (GCs) in the short term and the increase in signs associated with the persistence of inflammatory activity and the accumulation of organ damage induced by GCs in the long term, which indicates the need for the use of therapy, primarily in the direction of optimizing the use of GCs. New opportunities for pharmacotherapy of GCA are associated with the use of monoclonal antibodies (mAbs) that block the activity of cytokines involved in the immunopathogenesis of IMIRDs. Among pharmacological “targets”, interleukin (IL) 6, as well as IL-17, attracts special attention. Currently, several mAbs specific for IL-17 have been developed. The article summarizes data regarding the pathogenetic significance of IL-17 in GCA and the prospects for pharmacotherapy of GCA using mAbs to IL-17.